N/A
Completed N=180
GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.
Source: ClinicalTrials.gov NCT01269125 ↗Enrolled (actual)
180
Serious AEs
3.3%
Results posted
Jul 2013
Primary outcomePrimary: Clinical Pregnancy Rate — 28.3; 25.4; 33.3 percentage — p=0.80
Summary
The investigators attempted to establish a rationale for the Gonadotropin Releasing Hormone-agonist (GnRH-a) administration, post-laparoscopically, in women with mild endometriosis (until stage II, according to AFS) who underwent IVF-ET procedure. Since GnRH-a reduces cytokine's concentration in serum (Iwabe et al., 1998; Iwabe et al., 2003) and peritoneal fluid of women with endometriosis (Taketani et al., 1992) the investigators hypothesized that GnRH-a can reduces also cytokine's concentration in the follicular fluid and this action may improve the oocyte quality and the fertility of these women.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Pregnancy Rate |
28.3; 25.4; 33.3 | 0.80 |
| PRIMARY Embryo Quality (the Percentage of Grade 1 Embryos Per Participant). |
25.5; 22.6; 27.0 | — |
| PRIMARY Fertilization Rate (Percentage of Fertilized Oocytes). |
73.7; 62.7; 75.7 | — |
| PRIMARY Clinical Pregnancy Rate |
28.3; 25.4; 33.3 | 0.80 |
| SECONDARY Follicular Fluid's TNF-a Concentration. |
21.4; 38.6; 22.5; 3.1; 9.3; 2.9 | — |
Eligibility Criteria
Inclusion Criteria
- Infertility
- Mild endometriosis (until stage II)
Exclusion Criteria
- ovarian endometrioma > 2 cm
- FSH > 12 mIU/ml
- Mail factor infertility
Data sourced from ClinicalTrials.gov (NCT01269125). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.